Navigation Links
CytRx Reports Promising Data from Its Open-Label Extension Clinical,Trial of Arimoclomol in ALS

istry and RNAi delivery. The Company was founded by CytRx and RNAi pioneers Craig Mello, Ph.D., 2006 Nobel Laureate for discovering RNAi and inventing RNAi therapeutics; Tariq M. Rana, Ph.D., inventor of fundamental technology for stabilizing RNAi and of RNAi nanotransporters; Greg Hannon, Ph.D., discoverer of RNAi mechanism (RISC) and short hairpin RNAi (shRNAi); and Michael Czech, Ph.D., a leader in the application of RNAi to diabetes and obesity. RXi's CEO, Tod Woolf, Ph.D., previously co-invented and commercialized STEALTH(TM) RNAi, one of the most widely used second-generation RNAi research products.

Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Such statements involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks or uncertainties regarding regulatory approvals for future clinical testing of arimoclomol, including CytRx's planned Phase IIb clinical trial, and the scope of the clinical testing that may be required by regulatory authorities for arimoclomol, risks related to any comparison of clinical data to historical controls in the absence of concurrent placebo controls, uncertainties regarding the timing and amount of revenues, if any, that will be realized by CytRx from the commercialization of arimoclomol, the significant time and expense that will be incurred in developing any of the potential commercial applications for arimoclomol and the potential need for additional capital to fund the development of arimoclomol, as well as other risks or uncertainties described in CytRx's most recently filed SEC documents, such as its most recent annual report on Form 10-K and any current reports on Form 8-K filed since the date of the last Form 10-K. All forward-looking statements are based upon informat
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS
2. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
3. CytRx Announces Positive Results of Arimoclomol in Preclinical Stroke Recovery Studies
4. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
5. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
6. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
7. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
8. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
9. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
10. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
11. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
Post Your Comments:
(Date:12/24/2014)... Mexico , Dec. 24, 2014  Novastem, ... of its first patient in its study for ... the American Stroke Association, ischemic strokes account for ... to enroll qualified patients in the study, entitled ... Administration of Allogeneic Mesenchymal Stem Cells and Intrathecal ...
(Date:12/24/2014)... , Dec. 24, 2014 Soligenix, ... late-stage biopharmaceutical company developing products that address unmet ... and biodefense, announced today that on December 24, ... offering. The Company raised approximately $2.3 ... intends to use the net proceeds from the ...
(Date:12/24/2014)... LONDON , December 24, 2014 /PRNewswire/ ... expected to grow at an average rate of 8.1%. ... and volume. Hip, knee and spine surgeries are the ... emerging economies they have a lower penetration. Increased number ... use of composites. Non-metallic orthopedic devices have gained popularity ...
Breaking Medicine Technology:Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3
... 23, 2011 Reportlinker.com announces that ... available in its catalogue: ... Analysis of Water and Wastewater Management ... http://www.reportlinker.com/p0506839/Global-Water-Market-Outlook-Strategic-Analysis-of-Water-and-Wastewater-Management-in-the-Pharmaceutical-Industry.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Water_dis ...
... PAREXEL International Corporation (NASDAQ: PRXL ) announced ... Healthcare Conference in Palos Verdes, CA.  Josef von Rickenbach, Chairman ... PAREXEL at 4:00 p.m.  PT on Wednesday, June 8, 2011. ... available through the "Investors" section of PAREXEL,s website ...
Cached Medicine Technology:Reportlinker Adds Global Water Market Outlook: Strategic Analysis of Water and Wastewater Management in the Pharmaceutical Industry 2Reportlinker Adds Global Water Market Outlook: Strategic Analysis of Water and Wastewater Management in the Pharmaceutical Industry 3Reportlinker Adds Global Water Market Outlook: Strategic Analysis of Water and Wastewater Management in the Pharmaceutical Industry 4PAREXEL International to Present at Goldman Sachs Healthcare Conference and Jefferies Global Healthcare Conference 2
(Date:12/25/2014)... 2014 The report “TS-1 (Colorectal Cancer) ... the current treatment landscape, unmet needs, current pipeline and ... an anti-cancer drug which is typically used for treating ... used for treating gastric cancer and pancreatic cancer. TS-1 ... drug was first approved in 1999 in Japan for ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 The short film ... was created in honor of a true 9/11 hero, Welles ... film festivals including the 24 hours of Nuremberg International Short ... Bangladesh. , Actress, screenwriter and director Luciana Lagana ... this film together with her husband, Gregory Graham ...
(Date:12/25/2014)... Recently, LunaDress.co.uk has updated its blog to provide professional shopping ... of the models at LunaDress.co.uk come with big discounts, up to ... veil can turn out to be a most exciting memory and ... always bring surprise to a wedding. On the updated fashion blog, ... veils for a big day . , Going out with friends ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. ... on a "fountain of youth" drug that can delay the ... a new study suggests. Seniors received a significant boost ... a genetic signaling pathway linked to aging and immune function, ... The experimental medication, a version of the drug rapamycin, improved ...
(Date:12/25/2014)... North Carolina (PRWEB) December 25, 2014 ... North Carolina Retirement Community, recently showed their generous ... girls of the Catawba County Parenting Network- Grandparents ... the 10 children gathered around the largest Christmas ... to open presents purchased by residents of the ...
Breaking Medicine News(10 mins):Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Retirement Community Residents Make Impact During Holiday Season 2
... Thousands of research studies have documented how the ... the cardiovascular system, particularly among people diagnosed with ... on this topic creates difficulty for many physicians ... recommendations related to these oils. In the March ...
... Intracranial hypertension left patients almost 5 times more likely ... News) -- Black Americans are more likely than other ... intracranial hypertension, or increased pressure in the brain, according ... School of Medicine in Atlanta reviewed the medical records ...
... a rare type of ovarian cancer, is less sensitive ... more common high-grade ovarian cancers, according to researchers from ... The findings were reported at the Society of Gynecologic ... retrospective study is the first to analyze how women ...
... March 10 Give an Hour, (http://www.giveanhour.org ), ... to returning Veterans and their loved ones,announces that ... network., In an effort to supplement the ... the military health care system, Give an Hour,s,services ...
... about climate change, energy security, and other concerns expressed ... USA launched From Electrons to Elections, a science and ... From Electrons to Elections is a non-partisan resource designed ... issues and provide them with the platforms of the ...
... be getting them, study says , , MONDAY, March 10 (HealthDay ... choices for kidney cancer more than clinical factors such as ... finds. , This means many patients who are candidates ... where only part of the kidney is removed, may not ...
Cached Medicine News:Health News:Mayo Clinic proceedings highlights research about cardiovascular benefits of omega-3 fatty acids 2Health News:Brain Disease Causes More Vision Loss in Blacks 2Health News:Recurrent low-grade carcinoma of the ovary less responsive to chemo than more common ovarian cancers 2Health News:Recurrent low-grade carcinoma of the ovary less responsive to chemo than more common ovarian cancers 3Health News:1,000 Mental Health Professionals Join National Network to Provide Free Counseling to Returning Veterans and their Families 2Health News:Student Pugwash USA launches science policy election guide for young voters 2Health News:Surgeon's Preferences Dictate Choice of Kidney Cancer Surgery 2Health News:Surgeon's Preferences Dictate Choice of Kidney Cancer Surgery 3
Instrument Cover for Vibratome....
This is a perfect tool for retrieving free floating sections from the Vibratome bath....
Vibratome Specimen Adhesive is a special formulation developed by a major adhesive manufacturer for applications such as tissue mounting. The advantage of this adhesive is that it has a strong holdi...
Specimen mounts are designed to allow for the rotation of the specimen in the Vibratome vice assembly for sectioning at different horizontal orientations....
Medicine Products: